Sirolimus
Sirolimus, also known as rapamycin, is a macrolide compound used primarily as an immunosuppressive and Mtor pathway inhibitor.
Sirolimus, also known as rapamycin, is a macrolide compound used primarily as an immunosuppressive and Mtor pathway inhibitor. It binds to FKBP12 and functionally suppresses mechanistic target of rapamycin complex 1 (mTORC1), thereby altering cell growth, proliferation, metabolism, and immune activation. Because of these effects, sirolimus has broad biomedical relevance in transplantation, hematology, vascular anomalies, and experimental aging research.
Clinically, sirolimus is used in regimens that require immune modulation, including hematopoietic cell transplantation and graft-versus-host disease prophylaxis, and it has also been investigated for difficult-to-treat pediatric vascular tumors and malformations such as kaposiform hemangioendothelioma and venous malformations. In recent research, it has also served as a pharmacologic probe for mTORC1-dependent biology in cancer, autophagy, and tissue remodeling, including pathways involving Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB)/mTOR signaling, Protein kinase B (PKB), PRKAA1, Sequestosome 1 (p62), and related regulators such as everolimus and melatonin.
Where the papers sit
16 papers from the last 6 months study sirolimus directly · updated from PubMed 16 Nov 2026
Study type 2 clinical trials · 5 observational · 8 preclinical · 1 unclassified
Themes 3 themes
-
Immune Modulation and Autoimmunity
Immune modulation is the main overlap, spanning plaque inflammation, transplantation, and autoimmune cytopenias. Sirolimus-based regimens are being tested to restrain cytokine responses and induce durable immune control, including in belatacept-supported islet transplantation. Atherosclerosis work emphasizes plaque stabilization and altered αβ T-cell responses, while hematology studies address refractory disease. The vertebral-artery imaging report and canine geroprotection study do not establish a shared therapeutic direction.
7 papers · 43.8%
-
Drug Delivery and Lymphatic Disorders
Controlled drug delivery dominates the engineering studies, with dendrimers, PLGA carriers, hydrogels, and 19F MRI used to tune localization, co-encapsulation, and release. Rapamycin formulations are being directed toward intracranial vascular therapy and postsurgical tumor cavities. Separate clinical reports support sirolimus for lymphangioma and lymphangioleiomyomatosis, including long-term treatment outcomes. These delivery and disease-management strands share the drug but do not form one unified research direction.
6 papers · 37.5%
-
mTOR Signaling in Disease
mTOR biology is being linked to disease-specific lipid handling, tissue injury, and cardiac remodeling. Computational screening seeks new mTOR inhibitors for feline hypertrophic cardiomyopathy, while biomaterial platforms explore sequential rapamycin delivery for spinal cord repair. In atherosclerosis, an mTORC1-NPC2 axis connects impaired lipophagy with plaque progression. The work is moving toward targeted modulation of mTOR pathways rather than nonspecific rapamycin exposure.
3 papers · 18.8%
Papers
The 16 papers from the last 6 months that study sirolimus directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Immune Modulation and Autoimmunity (7)
- Sex-stratified immune patterns across the canine lifespan and short-term responses to geroprotective interventions. Biogerontology · 6 Oct 2026 PMID 42837017
- Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice. Aging cell · 23 Sept 2026 PMID 42775680
- A multi-centre study of belatacept and sirolimus for islet transplantation. Diabetologia · 18 Aug 2026 PMID 42608595
- Neuro-images: "string of beads" at vertebral artery origin: 3-year angiographic follow-up after stenting for fibromuscular dysplasia. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 14 Aug 2026 PMID 42601533
- uPAR-Guided Dendrimer Gel Nanoparticles Reprogram Inflammation to Stabilize Atherosclerotic Plaques. ACS applied materials & interfaces · 24 Jun 2026 PMID 42340987
- Sirolimus for refractory/relapsed warm autoimmune hemolytic anemia and Evans syndrome: a prospective study. Blood advances · 9 Jun 2026 PMID 42263666
- Sirolimus-based treatment regimens for antinuclear antibody (ANA)-positive immune thrombocytopenia: a retrospective single-center cohort study. Hematology (Amsterdam, Netherlands) · 25 May 2026 PMID 42179326
Drug Delivery and Lymphatic Disorders (6)
- 19F MRI-Traceable PLGA Nanocarriers: Influence of Particle Architecture on Co-Encapsulation and Release of Immiscible Payloads. ACS biomaterials science & engineering · 25 Oct 2026 PMID 42927603
- Micro-modulation of the intra-structural environment in electrospun drug delivery systems: effects on drug release and hydrolytic degradation. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 19 Sept 2026 PMID 42762970
- Successful management of lymphangioma circumscriptum of the tongue with sirolimus monotherapy: a case report. Oral and maxillofacial surgery · 26 Jul 2026 PMID 42503529
- Design and validation of a poly-L-lysine dendrimer-based rapamycin delivery system for intracranial drug-coated balloons. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 18 Jun 2026 PMID 42315038
- Light-driven thermotropic hydrogel with nanomodulator enables lipid intervention and cavity delivery for postsurgical tumor therapy. Cell reports. Medicine · 18 Jun 2026 PMID 42314685
- Long-term outcomes of sirolimus therapy in sporadic and tuberous sclerosis complex-associated lymphangioleiomyomatosis: a retrospective cohort study. Polish archives of internal medicine · 12 Jun 2026 PMID 42284501
mTOR Signaling in Disease (3)
- A novel mTORC1-NPC2 axis suppresses lipophagy and drives atherosclerotic plaque progression. Biochimica et biophysica acta. Molecular basis of disease · 9 Sept 2026 PMID 42716142
- Sequential delivery of STING inhibitor and rapamycin by a Sr-Zn mesoporous bioactive glass platform for spinal cord injury repair. Journal of controlled release : official journal of the Controlled Release Society · 25 Jul 2026 PMID 42501804
- In Silico Discovery of mTOR Inhibitors as Potential Therapeutics for Feline Hypertrophic Cardiomyopathy. Journal of molecular modeling · 29 Jun 2026 PMID 42371166
By study type
Clinical trials (2)
- A multi-centre study of belatacept and sirolimus for islet transplantation. Diabetologia · 18 Aug 2026 PMID 42608595
- Sirolimus for refractory/relapsed warm autoimmune hemolytic anemia and Evans syndrome: a prospective study. Blood advances · 9 Jun 2026 PMID 42263666
Observational studies and case reports (5)
- Sex-stratified immune patterns across the canine lifespan and short-term responses to geroprotective interventions. Biogerontology · 6 Oct 2026 PMID 42837017
- Neuro-images: "string of beads" at vertebral artery origin: 3-year angiographic follow-up after stenting for fibromuscular dysplasia. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 14 Aug 2026 PMID 42601533
- Successful management of lymphangioma circumscriptum of the tongue with sirolimus monotherapy: a case report. Oral and maxillofacial surgery · 26 Jul 2026 PMID 42503529
- Long-term outcomes of sirolimus therapy in sporadic and tuberous sclerosis complex-associated lymphangioleiomyomatosis: a retrospective cohort study. Polish archives of internal medicine · 12 Jun 2026 PMID 42284501
- Sirolimus-based treatment regimens for antinuclear antibody (ANA)-positive immune thrombocytopenia: a retrospective single-center cohort study. Hematology (Amsterdam, Netherlands) · 25 May 2026 PMID 42179326
Preclinical: animal, cell and lab studies (8)
- 19F MRI-Traceable PLGA Nanocarriers: Influence of Particle Architecture on Co-Encapsulation and Release of Immiscible Payloads. ACS biomaterials science & engineering · 25 Oct 2026 PMID 42927603
- Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice. Aging cell · 23 Sept 2026 PMID 42775680
- Micro-modulation of the intra-structural environment in electrospun drug delivery systems: effects on drug release and hydrolytic degradation. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 19 Sept 2026 PMID 42762970
- Sequential delivery of STING inhibitor and rapamycin by a Sr-Zn mesoporous bioactive glass platform for spinal cord injury repair. Journal of controlled release : official journal of the Controlled Release Society · 25 Jul 2026 PMID 42501804
- In Silico Discovery of mTOR Inhibitors as Potential Therapeutics for Feline Hypertrophic Cardiomyopathy. Journal of molecular modeling · 29 Jun 2026 PMID 42371166
- uPAR-Guided Dendrimer Gel Nanoparticles Reprogram Inflammation to Stabilize Atherosclerotic Plaques. ACS applied materials & interfaces · 24 Jun 2026 PMID 42340987
- Design and validation of a poly-L-lysine dendrimer-based rapamycin delivery system for intracranial drug-coated balloons. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 18 Jun 2026 PMID 42315038
- Light-driven thermotropic hydrogel with nanomodulator enables lipid intervention and cavity delivery for postsurgical tumor therapy. Cell reports. Medicine · 18 Jun 2026 PMID 42314685
Unclassified: not yet indexed with MeSH (1)
- A novel mTORC1-NPC2 axis suppresses lipophagy and drives atherosclerotic plaque progression. Biochimica et biophysica acta. Molecular basis of disease · 9 Sept 2026 PMID 42716142
Written from 16 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.